<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
    <meta name="viewport" content="width=device-width; initial-scale=1.0; maximum-scale=1.0; user-scalable=no;">
    <meta http-equiv="X-UA-Compatible" content="IE=9; IE=8; IE=7; IE=EDGE" />

    <title></title>

    <style type="text/css"> 
        @media screen and (-webkit-min-device-pixel-ratio:0) {
            center {
                font-family: Arial, Helvetica, sans-serif;
            }
        }

        body {
            background-color: #fff;
            font-family: Arial, Helvetica, sans-serif;
            margin: auto;
            padding: 0;
            width: 600px;
        }

        h1 {
            color: #34495E;
            display: block;
            font-size: 1rem;
            font-weight: 100;
            line-height: 1.4rem;
        }

        h2 {
            color: #424949;
            font-size: .8rem;
            font-weight: 100; 
            margin-top: 1.7rem;
        }
        
        h3 {
            color: #4D5656;
            font-size: .7rem;
            font-weight: 100; 
        }

        a:visited, a:link, a:active {
            color: #000;
            text-decoration: none;
        }

        .subscript {
            font-size: .7rem;
        }

        .body {
            margin: auto;
            width: 72%;
        }

        /* images */
        .img-header {
            padding: 1rem;
            width: 85%;
        }

        .img-body {
            padding: 1rem;
            width: 75%;
        }

        .img-footer {
            padding: 1.5rem;
            height: 30%;
            width: 25%;

        }

        .flex-row {
            display: flex;
            flex-direction: row;
        }

    </style>


</head>

<body>

   <!-- Header --> 
    <table role="presentation" border="1px solid" cellspacing="0" width="100%">
        <tr>
            <td>
                <center><img src="public/images/til_03.png" class="img-header"></center>
            </td>
        </tr>
    </table>
        
    <!-- Body 1 --> 
    <div class="body">
        <table role="presentation" border="1px solid" cellspacing="0" width="100%">
            <tr>
                <td>
                    <h1>Tumor infiltrating lymphocytes (TIL) are part of the body's natural response to cancer. 
                        For patients who have not responded to or who have progressed on immune checkpoint 
                        inhibitors, TIL are being investigated as a potential treatment option in multiple 
                        solid tumors.<sup class="subscript">1-3</sup></h1>
                    
                    <center><img src="public/images/learn_more_07.jpg" class="img-body"></center>
                    
                    <h1>
                        IOVANCE Biotherapeutics is committed to deepening the
                        understanding of TIL and optimizing TIL technology to help
                        shape the next chapter of TIL cell therapy.
                    </h1>
                
                    <center><img src="public/images/visit_link_10.jpg" class="img-body"></center>
                </td> 
            </tr>
        </table>

        <!-- Body 2 -->
        <table role="presentation" border="1px solid" cellspacing="0" width="100%">
            <tr>
                <td>
                    <h3>
                        <b>References: 1.</b> Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive
                        immunotherapy of cancer with tumor-infiltrating lymphocytes. <i>Science.</i>
                        1986;233:1318-1321. <b>2.</b> Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint
                        inhibitors: recent progress and potential biomarkers. <i>Exp Mol Med.</i> 2018;50(12):165.
                        <b>3.</b> Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1
                        blockade. <i>Cancer J.</i> 2018;24(1):47-53.
                    </h3>
                </td> 
            </tr>
        </table>
    </div>
        
    <!-- Footer -->
    <table role="presentation" border="1px solid" cellspacing="0" width="100%">
        <tr>
            <td> 
                <div class="flex-row">
                    <img src="public/images/iovance_logo_13.png" class="img-footer">
                
                    <h2>
                        <a href="">CONTACT US</a> | <a href="">PRIVACY POLICY</a> | <a href="">UNSUBSCRIBE</a><br><br>
                
                        Iovance Biotherapeutics<br>
                        999 Skyway Rd<br>
                        Suite 150<br>
                        SanCarlos, CA 94070<br><br>
                
                        Â© 2020 IOVANCE Biotherapeutics, Inc. All Rights Reserved.<br>
                        IOVANCE logo is a trademark owned by Iovance<br>
                        Biotherapeutics, Inc.<br>
                        PRC-US-00032(v1.0)<br>
                    </h2>
                </div>
            </td>
        </tr>
    </table> 





</body>
</html>